CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-14 | Chadwick Jeremy G Chief Operating Officer | Option exercise 10b5-1 | +4,466 | $30.17 | $135K | 65,668 |
| 2026-04-14 | Chadwick Jeremy G Chief Operating Officer | Option exercise 10b5-1 | +785 | $43.50 | $34K | 66,453 |
| 2026-04-14 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −5,251 | $90.00 | $473K | 61,202 |
| 2026-04-14 | Chadwick Jeremy G Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,466 | 45,534 | ||
| 2026-04-14 | Chadwick Jeremy G Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −785 | 59,763 | ||
| 2026-04-10 | Goodman Noah Chief Business Officer | Sale 10b5-1 | −2,000 | $87.35 | $175K | 51,542.44 |
| 2026-04-09 | Goodman Noah Chief Business Officer | Option exercise 10b5-1 | +2,500 | $21.05 | $53K | 61,806.44 |
| 2026-04-09 | Goodman Noah Chief Business Officer | Sale 10b5-1 | −3,094 | $86.62 | $268K | 58,712.44 |
| 2026-04-09 | Goodman Noah Chief Business Officer | Sale 10b5-1 | −2,670 | $87.11 | $233K | 56,042.44 |
| 2026-04-09 | Goodman Noah Chief Business Officer | Sale 10b5-1 | −2,500 | $89.00 | $223K | 53,542.44 |
| 2026-04-09 | Goodman Noah Chief Business Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,500 | 97,500 | ||
| 2026-04-01 | Ridloff Elena Director | Option exercise 10b5-1 | +4,600 | $14.18 | $65K | 4,600 |
| 2026-04-01 | Ridloff Elena Director | Sale 10b5-1 | −3,400 | $85.19 | $290K | 1,200 |
| 2026-04-01 | Ridloff Elena Director | Sale 10b5-1 | −1,200 | $86.05 | $103K | 0 |
| 2026-04-01 | Ridloff Elena Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,600 | 0 | ||
| 2026-04-01 | Chadwick Jeremy G Chief Operating Officer | Option exercise 10b5-1 | +14,640 | $29.64 | $434K | 75,842 |
| 2026-04-01 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −13,540 | $85.41 | $1.2M | 62,302 |
| 2026-04-01 | Chadwick Jeremy G Chief Operating Officer | Sale 10b5-1 | −1,100 | $86.05 | $95K | 61,202 |
| 2026-04-01 | Chadwick Jeremy G Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,640 | 68,633 | ||
| 2026-03-31 | Ridloff Elena Director | Option exercise 10b5-1 | +7,400 | $14.18 | $105K | 7,400 |
Page 13 of 25 · 493 trades